Probiotics in Adhesion of Pathogens: Mechanisms of Action

Bioactive Foods in Promoting Health: Probiotics and Prebiotics

Volumn , Issue , 2010, Pages 353-370

  Collado, Maria Carmen ^a,b   Gueimonde, Miguel ^b,c   Salminen, Seppo ^b  

^a INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

^b UNIVERSITY OF TURKU   (Finland)

^c DEPARTMENT OF MICROBIOLOGY AND BIOCHEMISTRY OF DAIRY PRODUCTS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85135634039     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374938-3.00023-2     Document Type: Chapter

References (144)

1. FAO/WHO (2002). Guidelines for the evaluation of probiotics in food. Food and Agricultural Organization of the United Nations and World Health Organization. Working Group Report 2002.
2. Collins J.K., Thornton G., Sullivan G.O. Selection of probiotic strains for human application. International Dairy Journal 1998, 8:487-490.
3. Ouwehand A.C., Salminen S., Isolauri E. Probiotics: an overview of beneficial effects. Antonie van Leeuwenhoek 2002, 82:279-289.
4. Timmerman H.M., Koning C.J., Mulder L., et al. Monostrain, multistrain and multispecies probiotics-A comparison of functionality and efficacy. International Journal of Food Microbiology 2004, 96:219-233.
5. Collado M.C., Meriluoto J., Salminen S. In vitro analysis of probiotic strains combinations to inhibit pathogen adhesion to human intestinal mucus. Food Res Int 2007, 40(5):629-636.
6. Forestier C., De Champs C., Vatoux C., Joly B. Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Research in Microbiology 2001, 152:167-173.
7. Collado M.C., Isolauri E., Salminen S. Role of probiotic strains and their combinations in Enterobacter sakazakii in vitro infection associated with powdered infant formula. FEMS Microbiology Letters 2008, 285(1):58-64.
8. Ng S.C., Hart A.L., Kamm M.A., et al. Mechanisms of action of probiotics: Recent advances. Inflammatory Bowel Diseases 2009, 15(2):300-310.
9. Corr S.C., Hill C., Gahan C.G. Chapter 1 understanding the mechanisms by which probiotics inhibit gastrointestinal pathogens. Advances in Food and Nutrition Research 2009, 56:1-15.
10. Collado M.C., Isolauri E., Salminen S., Sanz Y. The impact of probiotic on gut health. Advances in Food and Nutrition Research 2009, 10(1):68-78.
11. Fooks L.J., Fuller R., Gibson G.R. Prebiotics, probiotics and human gut microecology. International Dairy Journal 1999, 9:53-61.
12. Servin A.L. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiology Reviews 2004, 28:405-440.
13. Bourlioux P., Koletzko B., Guarner F., Braesco V. The intestine and its microflora are partners for the protection of the host: Report on the Danone Symposium 'The Intelligent Intestine,' held in Paris, June 14, 2002. The American Journal of Clinical Nutrition 2003, 78(4):183-675.
14. Neutra M.R., Forstner J.F. Gastrointestinal mucus: Synthesis, secretion and function. Physiology of the Gastrointestinal Tract 1987, Raven Press, New York. 2nd edn. L.R. Johnson (Ed.).
15. Juntunen M., Kirjavainen P.V., Ouwehand A.C., et al. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diag Lab Immunol 2001, 8(2):293-296.
16. López-Ferrer A., de Bolós C., Barranco C., et al. Role of fucosyltransferases in the association between apomucin and Lewis antigen expression in normal and malignant gastric epithelium. Gut 2000, 47(3):349-356.
17. Deplancke B., Gaskins H.R. Microbial modulation of innate defense: Goblet cells and the intestinal mucus layer. The American Journal of Clinical Nutrition 2001, 73:1131S-1141S.
18. Montagne L., Piel C., Lallés J.P. Effect of diet on mucin kinetics and composition: Nutrition and health implications. Nutrition Reviews 2004, 62:105-114.
19. Hamer H.M., Jonkers D., Venema K., et al. Review article: The role of butyrate on colonic function. Alimentary Pharmacology & Therapeutics 2008, 27(2):104-119.
20. Forstner J.F. Intestinal mucins in health and disease. Digestion 1978, 17(3):234-263.
21. Collado M.C., Ben-Amor K., Salminen S., de Vos W. The mucin-degrader Akkermansia muciniphila is an important member of the human intestinal tract. Applied and Environmental Microbiology 2008, 74:1646-1648.
22. Collado M.C., Derrien M., Isolauri E., et al. Intestinal integrity and Akkermansia muciniphila: A mucin-degrading member of the intestinal microbiota present in infants, adults and the elderly. Applied and Environmental Microbiology 2007, 73(22):7767-7770.
23. Dekker J., Rossen J.W., Büller H.A., Einerhand A.W. The MUC family: An obituary. Trends in Biochemical Sciences 2002, 27(3):126-131.
24. Dharmani P., Srivastava V., Kissoon-Singh V., Chadee K. Role of intestinal mucins in innate host defense mechanisms against pathogens. Journal of Innate Immunity 2009, 1:123-135.
25. Forstner, J. F., Oliver, M. G. & Sylvester, F. A., 1995. Production, structure and biologic relevance of gastrointestinal mucins. In Infections of the Gastrointestinal Tract (Chapter 5). New York: Raven Press.
26. Niku-Paavola M.L., Laitila A., Mattila-Sandholm T., Haikara A. New types of antimicrobial compounds produced by Lactobacillus plantarum. Journal of Applied Microbiology 1999, 86:29-35.
27. Chen H., Hoover D.G. Bacteriocins and their food applications. Comprehensive Rev Food Sci Food Safety 2003, 2:82-100.
28. Ibrahim S.A., Bezkorovainy A. Survival of bifidobacteria in the presence of bile salt. Journal of the Science of Food and Agriculture 1993, 62:351-354.
29. Bruno F.A., Shah N.P. Inhibition of pathogenic and putrefactive microorganisms by Bifidobacterium sp. Milchwissenschaft 2002, 57:617-621.
30. Daniels J.A., Krishnamurthi R., Rizvi S.S.H. A review of the effects of carbon dioxide on microbial growth and food quality. Journal of Food Protection 1985, 6:532-537.
31. Riley M.A., Wertz E. Bacteriocins: evolution, ecology and application. Annual review of microbiology 2002, 56:117-137.
32. Boris S., Barbes C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes and Infection 2000, 2:543-546.
33. Klaenhammer T.R. Functional activities of Lactobacillus probiotics: Genetic mandate. International Dairy Journal 1998, 8:497-505.
34. Touré R., Kheardr E., Lacroix C., et al. Production of antibacterial substances by bifidobacterial isolates from infant stool active against Listeria monocytogenes. Journal of Applied Microbiology 2003, 95:1058-1069.
35. Collado M.C., Hernández M., Sanz Y. Production of bacteriocin-like inhibitory compounds by potentially probiotic bifidobacteria. Journal of food protection 2005, 68(5):1034-1040.
36. Collado M.C., González A., González R., et al. Antimicrobial peptides are within the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori. International Journal of Antimicrobial Agents 2005, 25:385-391.
37. Yildirim Z., Johnson M.G. Characterization and antimicrobial spectrum of bifidocin B, a bacteriocin produced by Bifidobacterium bifidum NCFB 1454. Journal of Food Protection 1998, 61:47-51.
38. Yildirim Z., Winters D.K., Johnson M.G. Purification, amino acid sequence and mode of action of bifidocin B produced by Bifidobacterium bifidum NCFB 1454. Journal of Applied Microbiology 1999, 86:45-54.
39. Lee Y.-J., Yu W.-K., Heo T.-R. Identification and screening for antimicrobial activity against Clostridium difficile of Bifidobacterium and Lactobacillus species isolated from healthy infant faeces. International Journal of Antimicrobial Agents 2003, 21:340-346.
40. Gagnon M., Kheadr E.E., Le Blay G., Fliss I. In vitro inhibition of Escherichia coli O157:H7 by bifidobacterial strains of human origin. International Journal of Food Microbiology 2004, 92:69-78.
41. Beachey E.H. Bacterial adherence: Adhesin-receptor interactions mediating the attachment of bacteria to mucosal surfaces. Journal of Infectious Diseases 1981, 143:325-345.
42. Schiffrin E.J., Brassart D., Servin A.L., et al. Immune modulation of blood leukocytes in humans by lactic acid bacteria: Criteria for strain selection. The American Journal of Clinical Nutrition 1997, 66:515S-520S.
43. Salminen S., Bouley C., Boutron-Ruault M.-C., et al. Functional Food science and gastrointestinal physiology and function. The British Journal of Nutrition 1998, 80:S147-S171.
44. Collado M.C., Gueimonde M., Hernández M., et al. Adhesion of selected Bifidobacterium strains to human intestinal mucus and its role in enteropathogen exclusion. Journal of Food Protection 2005, 68(12):2672-2678.
45. Crociani J., Grill J.P., Huppert M., Ballongue J. Adhesion of different bifidobacterias strains to human enterocyte-like Caco-2 cells and comparison with in vivo study. Letters in Applied Microbiology 1995, 21:146-148.
46. Castagliuolo I., Galeazzi F., Ferrari S., et al. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. FEMS Immunol Med Microbiol 2005, 43(2):197-204.
47. O'Halloran F.M., Morrissey S.D., Murphy L., et al. Adhesion of potential probiotic bacteria to human epithelial cell lines. International Dairy Journal 1998, 8:596.
48. Perdigon G., Maldonado Galdeano C., Valdez J.C., Medici M. Interaction of lactic acid bacteria with the gut immune system. European journal of clinical nutrition 2002, 56(4):S21-26.
49. Jin L.Z., Marquardt R.R., Zhao X. A strain of Enterococcus faecium (18C23) inhibits adhesion of enterotoxigenic Escherichia coli K88 to porcine small intestine mucus. Applied and Environmental Microbiology 2000, 66:4200-4204.
50. Hirano J., Yoshida T., Sugiyama T., et al. The effect of Lactobacillus rhamnosus on enterohemorrhagic Escherichia coli infection of human intestinal cells in vitro. Microbiology and Immunology 2003, 47:405-409.
51. Voltan S., Castagliuolo I., Elli M., et al. Aggregating phenotype in Lactobacillus crispatus determines intestinal colonization and TLR2 and TLR4 modulation in murine colonic mucosa. Clinical and Vaccine Immunology 2007, 14(9):1138-1148.
52. Freter M. Factors affecting the microecology of the gut. Probiotics. The Scientific basis 1992, 111-145. Chapman and Hall, Glasgow. R. Fuller (Ed.).
53. Busscher H.J., Weerkamp A.H. Specific and non-specific interactions in bacterial adhesion to solid substrata. FEMS Microbiology Reviews 1987, 46:165-173.
54. Tuomola E.M., Ouwehand A.C., Salminen S. The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus. FEMS Immunology and Medical Microbiology 1999, 26:137-142.
55. Ofek I., Beachey E.H. Bacterial adherence. Advances in Internal Medicine 1980, 25:503-532.
56. Vigeant M.A., Ford R.M., Wagner M., Tamm L.K. Reversible and irreversible adhesion of motile Escherichia coli cells analyzed by total internal reflection aqueous fluorescence microscopy. Applied and Environmental Microbiology 2002, 68:2794-2801.
57. An Y.H., Dickinson R.B., Doyle R.J. Mechanisms of bacterial adhesion and pathogenesis of implant and tissue infections. Handbook of bacterial adhesion: Principles, Methods and Applications 2000, 1-28. Humana Press, Totowa. Y.H. An, R.J. Friedman (Eds.).
58. Dunne C., O'Mahony L., Murphy L., et al. In vitro selection criteria for probiotic bacteria of human origin: Correlation with in vivo findings. The American Journal of Clinical Nutrition 2001, 73:386S-392S.
59. Mack D.R., Ahrne S., Hyde L., et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003, 52(6):827-833.
60. Mack D.R., Michail S., Wei S., et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. The American Journal of Physiology 1999, 276:G941-G950.
61. Mattar A.F., Teitelbaum D.H., Drongowski R.A., et al. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatric Surgery International 2002, 18:586-590.
62. Furrie E., Macfarlane S., Kennedy A., et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 2005, 54(2):242-249.
63. Wehkamp J., Harder J., Wehkamp K., et al. NF-κB- and AP-1-mediated induction of human b-defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: A novel effect of a probiotic bacterium. Infection and Immunity 2004, 72(10):5750-5758.
64. Schlee M., Harder J., Koten B., et al. Probiotic lactobacilli and VSL#3 induce enterocyte b-defensin 2. Clinical and Experimental Immunology 2008, 151(3):528-535.
65. Todoriki K., Mukai T., Sato S., Toba T. Inhibition of adhesion of food-borne pathogens to Caco-2 cells by Lactobacillus strains. Journal of Applied Microbiology 2001, 91:154-159.
66. Fuller R. Ecological studies on the Lactobacillus flora associated with the crop epithelium of the fowl. The Journal of Applied Bacteriology 1973, 36:131-139.
67. Conway P.L., Gorbach S.L., Goldin B.R. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. Journal of Dairy Science 1987, 70:1-12.
68. Rinkinen M., Westermarck E., Salminen S., Ouwehand A.C. Absence of host specificity for in vitro adhesion of probiotic lactic acid bacteria to intestinal mucus. Veterinary Microbiology 2003, 97:55-61.
69. Nikoskelainen S., Salminen S., Bylund G., Ouwehand A.C. Characterization of the properties of human- and dairy-derived probiotics for prevention of infectious diseases in fish. Applied and Environmental Microbiology 2001, 67:2430-2435.
70. Nikoskelainen S., Ouwehand A.C., Salminen S., Bylund G. Protection of rainbow trout (Oncorhynchus mykiss) from furunculosis by Lactobacillus rhamnosus. Aquaculture 2001, 198:229-236.
71. Le Bouguénec C. Adhesins and invasins of pathogenic Escherichia coli. International Journal of Medical Microbiology 2005, 295(6-l7):471-478.
72. Weissman S.J., Moseley S.L., Dykhuizen D.E., Sokurenko E.V. Enterobacterial adhesins and the case for studying SNPs in bacteria. Trends Microbiol 2003, 11(3):115-117.
73. Weidenmaier C., Kokai-Kun J.F., Kristian S.A., et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nature Medicine 2004, 10:243-245.
74. Weidenmaier C., Peschel A., Xiong Y.Q., et al. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. The Journal of Infectious Diseases 2005, 191:1771-1777.
75. Sherman L.A., Savage D.C. Lipoteichoic acids in Lactobacillus strains that colonize the mouse gastric epithelium. Applied and Environmental Microbiology 1986, 52:302-304.
76. Granato D., Perotti F., Masserey I., et al. Cell surface-associated lipoteichoic acid acts as an adhesion factor for attachment of Lactobacillus johnsonii La1 to human enterocyte-like Caco-2 cells. Applied and Environmental Microbiology 1999, 65:1071-1077.
77. Ruas-Madiedo P., Gueimonde M., Margolles A., et al. Exopolysaccharides produced by probiotic strains modify the adhesion of probiotics and enteropathogens to human intestinal mucus. Journal of Food Protection 2006, 69(8):2011-2015.
78. Sun J., Le G.W., Shi Y.H., Su G.W. Factors involved in binding of Lactobacillus plantarum Lp6 to rat small intestinal mucus. Letters in Applied Microbiology 2007, 44(1):79-85.
79. Henriksson A., Conway P.L. Adhesion of Lactobacillus fermentum 104-S to porcine stomach mucus. Current Microbiology 1996, 33:31-34.
80. Adlerberth I., Cerquetti M., Poilane I., et al. Mechanisms of colonisation and colonisation resistance of the digestive tract. Microbial Ecology in Health and Disease 2000, 11:223-239.
81. Bergonzelli G.E., Granato D., Pridmore R.D., et al. GroEL of Lactobacillus johnsonii La1 (NCC 533) is cell surface associated: potential role in interactions with the host and the gastric pathogen Helicobacter pylori. Infection and Immunity 2006, 74:425-434.
82. Buck B.L., Altermann E., Svingerud T., Klaenhammer T.R. Functional analysis of putative adhesion factors in Lactobacillus acidophilus NCFM. Applied and Environmental Microbiology 2005, 71:8344-8351.
83. Coconnier M.H., Klaenhammer T.R., Kerneis S., et al. Protein mediated adhesion of Lactobacillus acidophilus BG2FO4 on human enterocyte and mucus-secreting cell lines in culture. Applied and Environmental Microbiology 1992, 58:2034-2039.
84. Granato D., Bergonzelli G.E., Pridmore R.D., et al. Cell surface-associated elongation factor Tu mediates the attachment of Lactobacillus johnsonii NCC533 (La1) to human intestinal cells and mucins. Infection and Immunity 2004, 72:2160-2169.
85. Henriksson A., Szewzyk R., Conway P.L. Characteristics of the adhesive determinants of Lactobacillus fermentum 104. Applied and Environmental Microbiology 1991, 57:499-502.
86. Miyoshi Y., Okada S., Uchimura T., Satoh E. A mucus adhesion promoting protein, MapA, mediates the adhesion of Lactobacillus reuteri to Caco-2 human intestinal epithelial cells. Bioscience, Biotechnology, and Biochemistry 2006, 70:1622-1628.
87. Roos S., Jonson H. A high-molecular-mass cell-surface protein from Lactobacillus reuteri 1063 adheres to mucus components. Microbiology 2002, 148:433-442.
88. Pretzer G., Snel J., Molenaar D., et al. Biodiversity-based identification and functional characterization of the mannose-specific adhesin of Lactobacillus plantarum. Journal of Bacteriology 2005, 187:6128-6136.
89. Thomas W.E., Trintchina E., Forero M., et al. Bacterial adhesion to target cells enhanced by shear force. Cell 2002, 109:123-913.
90. McGroarty J.A. Cell surface appendages of lactobacilli. FEMS Microbiology Letters 1994, 124:405-410.
91. Schell M.A., Karmirantzou M., Snel B., et al. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proceedings of the National Academy of Science 2002, 99:14422-14427.
92. Yamada M., Saito T., Toba T., et al. Hemagglutination activity of Lactobacillus acidophilus group lactic acid bacteria. Bioscience, Biotechnology, and Biochemistry 1994, 58:910-915.
93. Matsumura A., Saito T., Arakuni M., et al. New binding assay and preparative trial of cell-surface lectin from Lactobacillus acidophilus group lactic acid bacteria. Journal of Dairy Science 1999, 82:2525-2529.
94. Hynönen U., Westerlund-Wikström B., Palva A., Korhonen T.K. Identification by flagellum display of an epithelial cell- and fibronectin-binding function in the SlpA surface protein of Lactobacillus brevis. Journal of Bacteriology 2002, 184:3360-3367.
95. Gueimonde M., Noriega L., Margolles A., et al. Ability of Bifidobacterium strains with acquired resistance to bile to adhere to human intestinal mucus. International Journal of Food Microbiology 2005, 101:341-346.
96. Larsen N., Nissen P., Willats W.G. The effect of calcium ions on adhesion and competitive exclusion of Lactobacillus ssp. and E. coli O138. International Journal of Food Microbiology 2007, 114:113-119.
97. Ouwehand A.C., Parhiala R., Salminen S., et al. Influence of the endogenous mucosal microbiota on the adhesion of probiotic bacteria in vitro. Microbial Ecology in Health and Disease 2004, 16:202-204.
98. Ouwehand A.C., Tuomola E.M., Tölkkö S., Salminen S. Assessment of adhesion properties of novel probiotic strains to human intestinal mucus. International Journal of Food Microbiology 2001, 64:119-126.
99. Ouwehand A.C., Isolauri E., Kirjavainen P.V., et al. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Letters in Applied Microbiology 2000, 30:10-13.
100. Collado M.C., Meriluoto J., Salminen S. Interactions between pathogens and lactic acid bacteria: aggregation and coaggregation abilities. Eur J Food Res Technol 2008, 226(5):1065-1073.
101. Haukioja A., Yli-Knuuttila H., Loimaranta V., et al. Oral adhesion and survival of probiotic and other lactobacilli and bifidobacteria in vitro. Oral Microbiology and Immunology 2006, 21:326-332.
102. Gueimonde M., Jalonen L., He F., et al. Adhesion and competitive inhibition and displacement of human enteropathogens by selected lactobacilli. Food Res Int 2006, 39(4):467-471.
103. Bernet M.F., Brassart D., Nesser J.R., Servin A.L. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enterophatogen-cell interactions. Applied and Environmental Microbiology 1993, 59:4121-4128.
104. Bibiloni R., Perez P.F., de Antoni G.L. Will a high adhering capacity in a probiotic strain guarantee exclusion of pathogens from intestinal epithelia?. Anaerobe 1999, 5:519-524.
105. Ouwehand A.C., Salminen S., Tolkko S., et al. Resected human colonic tissue: New model for characterizing adhesion of lactic acid bacteria. Clinical and Diagnostic Laboratory Immunology 2002, 9:184-186.
106. Ouwehand A.C., Salminen S., Tolkko S., et al. Dependent adhesion of lactic acid bacteria to colonic tissue in vitro. Microecol Ther 2002, 29:95-102.
107. Haller D., Colbus H., Ganzle M.G., et al. Metabolic and functional properties of lactic acid bacteria in the gastro-intestinal ecosystem: A comparative in vitro study between bacteria of intestinal and fermented food origin. Systematic and Applied Microbiology 2001, 24:218-226.
108. De Waard R., Snel J., Bokken G.C., et al. Comparison of faecal Lactobacillus populations in experimental animals from different breeding facilities and possible consequences for probiotic studies. Letters in Applied Microbiology 2002, 34:105-109.
109. Rolfe R.D. The role of probiotic cultures in the control of gastrointestinal health. The Journal of Nutrition 2000, 130:396S-402S.
110. Reid G., Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes and Infection 2002, 4:319-324.
111. Schiffrin E.J., Blum S. Interactions between the microbiota and the intestinal mucosa. European Journal of Clinical Nutrition 2002, 56:S60-S64.
112. Nesser J.-R., Granato D., Rouvet M., et al. Lactobacillus johnsonii La1 shares carbohydrate-binding specificities with several enteropathogenic bacteria. Glycobiology 2000, 10:1193-1199.
113. Fujiwara S., Hashiba H., Hirota T., Forstner J.F. Inhibition of the binding of enterotoxigenic Escherichia coli Pb176 to human intestinal epithelial cell line HCT-8 by an extracellular protein fraction containing BIF of Bifidobacterium longum SBT2928: Suggestive evidence of blocking of the binding receptor gangliotetraosylceramide on the cell surface. International Journal of Food Microbiology 2001, 67:97-106.
114. Mukai T., Asasaka T., Sato E., et al. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunology and Medical Microbiology 2002, 32:105-110.
115. Coconnier M.H., Bernet M.F., Chauviere G., Servin A.L. Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells. Journal of Diarrhoeal Diseases Research 1993, 11:235-242.
116. Hirn J., Nurmi E., Johansson T., Nuotio L. Long-term experience with competitive exclusion and salmonellas in Finland. International Journal of Food Microbiology 1992, 15:281-285.
117. Genovese K.J., Anderson R.C., Harvey R.B., Nisbet D.J. Competitive exclusion treatment reduces the mortality and fecal shedding associated with enterotoxigenic Escherichia coli infection in nursery-raised neonatal pigs. Canadian Journal of Veterinary Research 2000, 64:204-207.
118. Gopal P.K., Prasad J., Smart J., Gill H.S. In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. International Journal of Food Microbiology 2001, 67:207-216.
119. Lesuffleur T., Porchet N., Aubert J.P., et al. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT29 cell sub-populations. Journal of Cell Science 1993, 106:771-783.
120. Kirjavainen P.V., Ouwehand A.C., Isolauri E., Salminen S.J. The ability of probiotic bacteria to bind to human intestinal mucus. FEMS Microbiology Letters 1998, 167:185-189.
121. Aissi E.A., Lecocq M., Brassart C., Buoquelet S. Adhesion of some Bifidobacteria strains to human enterocyte-like cells and binding to mucosal glycoproteins. Microbial Ecology in Health and Disease 2001, 13:32-39.
122. Tuomola E.M., Ouwehand A.C., Salminen S. Chemical, physical and enzymatic pre-treatments of probiotic lactobacilli alter their adhesion to human intestinal mucus glycoproteins. International Journal of Food Microbiology 2000, 60:75-81.
123. Ouwehand A.C., Salminen S. In vitro adhesion assays for probiotics and their in vivo relevance: A review. Microbial Ecology in Health and Disease 2003, 15:175-184.
124. Vesterlund S., Paltta J., Karp M., Ouwehand A.C. Measurement of bacterial adhesion-in vitro evaluation of different methods. Journal of Microbiological Methods 2005, 60:225-233.
125. Ibnou-Zekri N., Blum S., Schiffrin E.J., von der Weid T. Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro. Infection and Immunity 2003, 71:428-436.
126. Collado M.C., Meriluoto J., Salminen S. Development of new probiotics by strains combination: Is it possible to improve the adhesion to intestinal mucus?. Journal of Dairy Science 2007, 90:2710-2716.
127. Femia A.P., Luceri C., Dolara P., et al. Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis 2002, 23(11):1953-1960.
128. Gionchetti P., Lammers K.M., Rizzello F., Campieri M. Probiotics and barrier function in colitis. Gut 2005, 54(7):898-900.
129. Myllyluoma E., Veijola L., Ahlroos T., et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy-a placebo-controlled, double-blind randomized pilot study. Alimentary Pharmacology & Therapeutics 2005, 21(10):1263-1272.
130. Kajander K., Hatakka K., Poussa T., et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Alimentary Pharmacology & Therapeutics 2005, 22(5):387-394.
131. Olivares M., Diaz-Ropero M.P., Gómez N., et al. The consumption of two new probiotic strains, Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711, boosts the immune system of healthy humans. International Microbiology 2006, 9(1):47-52.
132. Roselli M., Finamore A., Britti M.S., Mengheri E. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. The British Journal of Nutrition 2006, 95(6):1177-1184.
133. Bibiloni R., Fedorak R.N., Tannock G.W., et al. VSLd3 probiotic-mixture induces remission in patients with active ulcerative colitis. The American Journal of Gastroenterology 2005, 100(7):1539-1546.
134. Kim H.J., Vazquez Roque M.I., Camilleri M., et al. A randomized controlled trial of a probiotic combination VSLd3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterology and Motility 2005, 17(5):687-696.
135. Gaudier E., Michel C., Segain J.P., et al. The VSLd 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice. The Journal of Nutrition 2005, 135(12):2753-2761.
136. Camilleri M. Probiotics and irritable bowel syndrome: Rationale, putative mechanisms, and evidence of clinical efficacy. Journal of Clinical Gastroenterology 2006, 40(3):264-269.
137. Kajander K., Myllyluoma E., Rajilić-Stojanović M., et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology & Therapeutics 2008, 27(1):48-57.
138. Kalliomäki M., Salminen S., Arvilommi H., et al. Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial. Lancet 2001, 357:1076-1079.
139. Kalliomäki M., Salminen S., Poussa T., et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003, 361(9372):1869-1871.
140. Kukkonen K., Savilahti E., Haahtela T., et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebo-controlled trial. The Journal of Allergy and Clinical Immunology 2007, 119(1):192-198.
141. Nybom S., Collado M.C., Surono I., et al. Effect of glucose in removal of microcystin-LR by commercial probiotic strains and strains isolated from dadih fermented milk. Journal of Agricultural and Food Chemistry 2008, 56(10):3714-3720.
142. Nybom S.M., Salminen S.J., Meriluoto J.A. Specific strains of probiotic bacteria are efficient in removal of several different cyanobacterial toxins from solution. Toxicon 2008, 52(2):214-220.
143. Halttunen T., Finell M., Salminen S. Arsenic removal by native and chemically modified lactic acid bacteria. International Journal of Food Microbiology 2007, 120(1-2):173-l178.
144. Halttunen T., Collado M.C., El-Nezami H., et al. Mixing of lactic acid bacteria strains may reduce their toxin removal efficiency from aqueous solution. Letters in Applied Microbiology 2008, 46(2):160-165.